Kaia Health | August 19, 2022
Kaia Health, the largest global digital therapeutics company on a mission to deliver the most effective digital therapies – anytime, anywhere, announced the addition of 3D full body mobility assessments, raising the bar for the standard of care delivery with motion analysis technology.
The technology creates a full 3D model of the body, removing the need for restrictive placement of the phone, and tracks the most important skeletal structures with an eye to what clinical teams care about most and with unparalleled precision. Tracking the most relevant points of any company in the world with high precision, allows continuous detection of subtle displacements and mobility limitations in the back, hip, knee, and ankles, something that neither in-person physical therapy or other virtual options can achieve. Using only a smartphone or tablet, there is no need for sensors or additional devices.
Using this quantitative data, members are provided with a personalized physical therapy program, real-time feedback, and specific exercises to help counteract mobility limitations. The technology also enables improved care design by the care team, a better understanding of the member’s progression over time, and as a result, improved clinical outcomes.
“With this new capability, we are able to deliver the most effective digital therapy experience by analyzing movement in real-time and providing a tailored program for each of our members. We are proud to be a world-leader in improving access to great care by delivering this innovative, clinically-validated solution to our members, driving better clinical outcomes and an optimal ROI at scale for our health plan and employer partners.”
Simon Hayhurst, chief product officer of Kaia Health
The global market for computer vision applied to healthcare is expected to reach $5.15 billion by 20261, and in recent months, the technology has seen rapid adoption among companies that provide MSK solutions.
Kaia Health is a pioneer in MSK technology and computer vision, having introduced it in 2018 with their exercise feedback and assessments capabilities. A study published in the peer-reviewed Journal of Medical Internet Research previously demonstrated Kaia Health’s technology to be as accurate as a physical therapist in suggesting exercise corrections.
About Kaia Health
Kaia Health is the world’s largest digital therapeutics company on a mission to empower millions of people to live their healthiest life. Our evidence-based treatments, covering a range of conditions, including musculoskeletal pain and COPD, are powered by proprietary motion analysis technology and clinical expertise. No sensors or wearables, Kaia’s programs need only a smartphone to deliver the most accessible, effective, and equitable experience for all. Eleven randomized clinical trials have shown Kaia’s effectiveness and safety to be as good as traditional care with up to 80% reduction in cost. Kaia Health is a member of the Digital Therapeutics Alliance (DTA) and is headquartered in NY and Munich. Kaia partners with leading health plans, employers, and providers, covering 60+ million lives around the world.
Sense Biodetection | September 02, 2022
Global molecular diagnostics innovator, Sense Biodetection announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform.
The self-contained, single-use Veros COVID-19 product produces PCR-quality results in about 15 minutes, unconstrained by a reader or need for external power. TECOmedical, a Eurobio Scientific Company, is a leading specialty medical distributor with proven success developing new markets with innovative technology. Effective immediately in Germany and Austria, and pending regulatory approval in Switzerland, the agreement is the latest in Sense’s planned EU distribution partnerships as it commercializes its Veros platform.
“We are delighted to partner with TECOmedical to bring Veros COVID-19 to the market, building on the impressive reputation that TECOmedical has established with their customers,” stated Ryan Roberts, Chief Commercial Officer of Sense. “We’re optimistic that by adding the instrument-free Veros COVID-19 to their diagnostic portfolio, TECOmedical’s customers will be able to take advantage of a laboratory-quality molecular test that can enable improved access and faster diagnosis, helping them to provide exceptional care for their patients right at the point of use.”
“We are always looking for innovative technologies that address an unmet need. Being able to offer an instrument free, PCR-quality result in minutes right at the Point of Care reflects our commitment to customers to bring solutions that help them overcome limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and are eagerly anticipating an expanded Veros test menu in the future.”
Marieluise Wippermann, CEO of TECOmedical
Veros is the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results in about 15 minutes. Using a proprietary, rapid molecular amplification technology, Veros aims to help to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses.
Veros COVID-19’s clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicentre study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read and understand the results, with minimal hands-on time required from start to finish.
As the virus continues to evolve, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants.
About Sense Biodetection
Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has launched its first product, Veros COVID-19, and is growing rapidly while building a portfolio of tests for other diseases.
The Swiss-based TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria is a leading provider of in-vitro specialty test systems in medical diagnostic, based on Immunosorbent, Immunofluorescence and Molecular methodologies.
Viveon Health Acquisition Corp. | July 16, 2022
Viveon Health Acquisition Corp. a special purpose acquisition company, and Suneva Medical, Inc. an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, announced that VHAQ filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 13, 2022.
The Registration Statement, contains a preliminary proxy statement/prospectus in connection with the previously announced business combination between VHAQ and Suneva. While the information within the Registration Statement is subject to change, it provides important information about Suneva Medical and VHAQ, as well as the proposed business combination.
On January 12, 2022, VHAQ entered into a merger agreement with Suneva. The combined company is expected to be listed on the NYSE American upon completion of the transaction, which is expected to occur in the second half of 2022, subject to approval by VHAQ’s shareholders, the Registration Statement being declared effective by the SEC, and other customary closing conditions.
Included in the Registration Statement are Suneva’s financial results for 2021 and for the first quarter of 2022. Overall, Suneva delivered strong revenue growth in 2021 and generated $29.5 million of net sales and $6.3 million in Q1 of 2022. Suneva’s full financial results and related disclosures can be found in the Registration Statement.
About Suneva Medical, Inc.
Suneva Medical, Inc., headquartered in San Diego, CA, is a leader in regenerative aesthetics. It is focused on developing, manufacturing and commercializing branded products for providers and their patients. Suneva offers a portfolio of products to address the impact of the aging process to deliver solutions that leverage the body’s own restorative capacity. The product portfolio is composed of several “only” and “first to market” solutions with both FDA PMA approval and 510(k) clearance.
About Viveon Health Acquisition Corp.
Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.